GCD Datasets in Progress
The Datasets in Progress table lists known global coherent datasets that are not yet sufficiently complete for release. Note that for datasets with more than one tissue the "approximate numbers of individuals" refers to the tissue with the greatest number of individuals and all tissues may not have this degree of coverage.
To add to or update this list please contact repdata@sagebase.org.
| Dataset Name | Tumor Tissue Type |
Species | Disease | Approx No Individuals |
Investigator | Institution | Reference PMID Description |
| Human_Cancer_Ovarian_TCGA | Ovarian | Human | Cancer | 387 | TCGA | TCGA | tcga.cancer.gov |
| Human_Cancer_Lung_TCGA | Lung | Human | Cancer | 500 | TCGA | TCGA | tcga.cancer.gov |
| Human_Cancer_HCC_NCI | HCC | Human | Cancer | 200 | Snorri Thorgeirsson | NCI | 19366792 |
| Human_Cancer_Lung_Canary | Lung | Human | Cancer | Canary | |||
| Human_Cancer_Pancreatic_ICGC | Pancreatic | Human | Cancer | 500 | ICGC | ICGC | Description |
| Human_Cancer_Ovarian_ICGC | Ovarian | Human | Cancer | 500 | ICGC | ICGC | Description |
| Human_Cancer_Gastric_ICGC | Gastric | Human | Cancer | 500 | ICGC | ICGC | Description |
| Human_Cancer_Breast (triple negative)_ICGC |
Breast (triple negative) |
Human | Cancer | 500 | ICGC | ICGC | Description |
| Human_Cancer_Breast(HER2) _ICGC |
Breast(HER2) | Human | Cancer | 500 | ICGC | ICGC | Description |
| Human_Cancer_HCC (viral) _ICGC |
HCC (viral) | Human | Cancer | 500 | ICGC | ICGC | Description |
| Human_Cancer_HCC (alcohol) _ICGC |
HCC (alcohol) | Human | Cancer | 500 | ICGC | ICGC | Description |
| Human_Cancer_Brain(pediatric) _ICGC |
Brain(pediatric) | Human | Cancer | 500 | ICGC | ICGC | Description |
| Human_Cancer_Oral_ICGC | Oral | Human | Cancer | 500 | ICGC | ICGC | Description |
| Human_Cancer_CLL_ICGC | CLL | Human | Cancer | 500 | ICGC | ICGC | Description |
| Human_Cancer_Glioblastoma _ICGC |
Glioblastoma | Human | Cancer | 500 | ICGC | ICGC | Description |
| Human_Cancer_Lung_ICGC | Lung | Human | Cancer | 500 | ICGC | ICGC | Description |
| Human_Cancer_AML_ICGC | AML | Human | Cancer | 500 | ICGC | ICGC | Description |
| Human_Cancer_Colon_ICGC | Colon | Human | Cancer | 500 | ICGC | ICGC | Description |
| Human_Cancer_Lung_ACRG | Lung | Human | Cancer | 2,000 | ACRG | ACRG | Description |
| Human_Cancer_Gastric_ACRG | Gastric | Human | Cancer | 2,000 | ACRG | ACRG | Description |
| Human_Cancer_Myeloma_Sage | Myeloma | Human | Cancer | 300 | Stephen Friend | Sage | Description |
| Human_Cancer_Lung_Sage | Lung | Human | Cancer | 300 | Stephen Friend | Sage | Description |
| Human_Cancer_Ovarian_Sage | Ovarian | Human | Cancer | 300 | Stephen Friend | Sage | Description |
| Human_Cancer_AML_Sage | AML | Human | Cancer | 300 | Stephen Friend | Sage | Description |
| Human_Cancer_Breast_Sage | Breast | Human | Cancer | 300 | Stephen Friend | Sage | Description |
| Human_Cancer_Medulloblastoma _JHSM |
Medulloblastoma | Human | Cancer | 47 | Bert Vogelstein | JHSM | Description |
| Human_Cancer_Pancreas_JHSM | Pancreas | Human | Cancer | 47 | Bert Vogelstein | JHSM | Description |
| Human_Cancer_Breast_NKI | Breast | Human | Cancer | 1,000 | Rene Bernards | NKI | Description |
| Human_Cancer_Colon_HKU | Colon | Human | Cancer | 400 | Suet-Yi Leung | HKU | Description |
Descriptions:
Human_Cancer_Pancreatic_ICGC
Human_Cancer_Ovarian_ICGC
Human_Cancer_Gastric_ICGC
Human_Cancer_Breast(triple negative)_ICGC
Human_Cancer_Breast(HER2)_ICGC
Human_Cancer_HCC (viral)_ICGC
Human_Cancer_HCC (alcohol)_ICGC
Human_Cancer_Brain(pediatric)_ICGC
Human_Cancer_Oral_ICGC
Human_Cancer_CLL_ICGC
Human_Cancer_Glioblastoma_ICGC
Human_Cancer_Lung_ICGC
Human_Cancer_AML_ICGC
Human_Cancer_Colon_ICGC
These cohorts all consist of prospectively collected matched tumor and adjacent normal tissue from 500 patients with particular cancer diagnosis. Data includes full genome DNA sequence, DNA methylation, mRNA Expression profiling, miRNA. Clinical outcomes available. www.icgc.org
Human_Cancer_Lung_ACRG
Eli Lilly and Company, Merck, and Pfizer Inc. have formed the Asian Cancer Research Group, Inc., (ACRG), an independent, not-for-profit company established to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asia. Over the next two years ACRG have committed to create one of the most extensive pharmacogenomic cancer databases known to date. This database will be composed of data from approximately 2,000 tissue samples from patients with lung and gastric cancer that will be made publicly available to researchers and, over time, further populated with clinical data from a longitudinal analysis of patients. Comparison of the contrasting genomic signatures of these cancers could inform new approaches to treatment
Human_Cancer_Gastric_ACRG
Eli Lilly and Company, Merck, and Pfizer Inc. have formed the Asian Cancer Research Group, Inc., (ACRG), an independent, not-for-profit company established to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asia. Over the next two years ACRG have committed to create one of the most extensive pharmacogenomic cancer databases known to date. This database will be composed of data from approximately 2,000 tissue samples from patients with lung and gastric cancer that will be made publicly available to researchers and, over time, further populated with clinical data from a longitudinal analysis of patients. Comparison of the contrasting genomic signatures of these cancers could inform new approaches to treatment
Human_Cancer_Myeloma_Sage
Clinical outcomes with responder/non-responder status for standard of care therapies. Partial retrospective, partial prospective. Patient-driven. Minimum full exome sequencing.
Human_Cancer_Lung_Sage
Clinical outcomes with responder/non-responder status for standard of care therapies. Partial retrospective, partial prospective. Patient-driven. Minimum full exome sequencing.
Human_Cancer_Ovarian_Sage
Clinical outcomes with responder/non-responder status for standard of care therapies. Partial retrospective, partial prospective. Patient-driven. Minimum full exome sequencing.
Human_Cancer_AML_Sage
Clinical outcomes with responder/non-responder status for standard of care therapies. Partial retrospective, partial prospective. Patient-driven. Minimum full exome sequencing.
Human_Cancer_Breast_Sage
Clinical outcomes with responder/non-responder status for standard of care therapies. Partial retrospective, partial prospective. Patient-driven. Minimum full exome sequencing.
Human_Cancer_Medulloblastoma_JHSM
Comprehensive data on DNA and mRNA (copy number, expression, sequence) from 47 medulloblastoma samples including sequence on >20,000 genes. Clinical outcomes available
Human_Cancer_Pancreas_JHSM
Comprehensive data on DNA and mRNA (copy number, expression, sequence) from 47 pancreatic cancer samples including sequence on >20,000 genes. Clinical outcomes available
Human_Cancer_Breast_NKI
A cohort of 1000 individuals with invasive breast cancer from the Netherlands. Comprehensive genomic data being generated from DAN and mRNA (copy number, expression, sequence). Clinical outcome data (median follow up 8 years)
Human_Cancer_Colon_HKU
A cohort of 400 individuals with colon carcinoma with RNA profiling (already generated), DNA genotyping (planned) and miRNA (planned). Clinical outcomes available.